Etalocib

Overview

Etalocib (LY293111), an orally active leukotriene B 4 receptor antagonist, inhibits the binding of [ 3 H]LTB 4 , with a K i of 25 nM. Etalocib (LY293111) prevents LTB 4 -induced calcium mobilization with an lC 50 of 20 nM. Etalocib (LY293111) induces apoptosis .

Application

Products | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Leukotriene Receptor | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-13628
• CAS No.: 161172-51-6
• Molecular Formula: C33H33FO6
• Molecular Weight: 544.61
• Purity: 99.03%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.5 mg/mL (4.59 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source